The FDA Peptide Hearing: 7 Compounds, One Question

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee met at the White Oak Campus in Silver Spring, Maryland, to review seven peptides for inclusion on the Section 503A Bulk Drug Substances List — the legal pathway that lets licensed compounding pharmacies prepare a substance for a patient with a valid prescription. We covered BPC-157 in depth recently. This article maps the other six, plus the regulatory context that applies to all seven.

If you’ve read our BPC-157 piece, the pattern here will feel familiar: extensive preclinical or international research, a real biological mechanism, genuine community enthusiasm — and a human evidence base in the United States that ranges from thin to nearly nonexistent.

Update — July 23–24, 2026: the committee overruled its own scientists

At the FDA’s White Oak campus, the advisory committee did something committees generally don’t: it told the agency’s own reviewers they’d read the data wrong.

The Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend BPC-157 and KPV for the 503A Bulks List — the list that lets licensed pharmacies compound a substance under prescription. TB-500 and MOTS-c cleared on separate votes the same afternoon. Four peptides, four recommendations — against the FDA’s own staff review, which had flagged no human clinical trials at all for KPV, TB-500, or MOTS-c; a single decades-old meeting abstract behind BPC-157’s ulcerative-colitis case; and three FAERS adverse-event reports tied to compounded injectables, including one emergency-room visit for shortness of breath.

Supporters’ case, boiled down: absence of proof isn’t proof of harm. The room went with it.

What actually changed, and what didn’t:

• This is a recommendation, not an approval. The FDA runs its own rulemaking next — public comment, formal review, realistically eight to twelve months before any pharmacy has clear legal footing, sometimes longer.
• A “no” vote wouldn’t have re-banned anything either. All seven peptides already came off the FDA’s Category 2 restricted list in April 2026. The question was whether a new legal channel opens — not whether the grey market disappears if it doesn’t.

Day two: the committee’s first “no”

The committee reconvened on July 24 for the remaining three — and this time it didn’t go three-for-three.

• Emideltide (DSIP) — rejected, roughly 6–7 with one abstention: the one clear loss of the two-day meeting. Proposed for insomnia, narcolepsy, and opioid withdrawal; FDA staff had flagged a theoretical addiction risk tied to its endorphin-release mechanism, on top of the usual small, uncontrolled trials.
• Epitalon — recommended, roughly 7–4, proposed for insomnia.
• Semax — recommended, 8–5, proposed for cerebral ischemia, migraine, and trigeminal neuralgia.

Final tally across both days: six of seven peptides recommended for the 503A Bulks List — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax cleared; Emideltide is the outlier. None of these are FDA approvals, and none are final: the agency runs its own rulemaking and isn’t bound by any of it.

The upshot. A regulatory vote is not a safety verdict. What changed this week is a paperwork pathway — pharmacies may eventually get a legal on-ramp to compound six of these seven peptides under prescription. What didn’t change is the evidence base: most of the six still have zero human trials behind their proposed uses, and the ones with data are working from small, uncontrolled studies. If the rule goes through, you’ll be paying out of pocket for something a prescription makes legal, not something a trial makes proven. Emideltide’s rejection is worth sitting with too — it’s the one result this week the “the FDA is just being cautious” framing doesn’t explain, since the same panel that waved through six peptides on thin evidence still said no to this one on safety grounds specifically.

Why this hearing is happening

In 2023, the FDA moved roughly 17-19 peptides to “Category 2” of the 503A Bulks List — the tier reserved for substances flagged with significant safety concerns, effectively prohibiting compounding pharmacies from preparing them. The stated reasons included unresolved immunogenicity risk, API characterization problems, and insufficient demonstrated clinical need.

In April 2026, the FDA removed twelve of those peptides from Category 2, including all seven discussed here. That removal lowered a barrier but didn’t create authorization — it set up this July’s PCAC hearing, where the committee would formally evaluate whether each peptide belongs on the Category 1 Bulks List. The four criteria: chemical characterization, safety for compounded use, evidence of effectiveness, and historical use in compounding.

Day 1 (July 23) covers BPC-157, TB-500, KPV, and MOTS-c — the tissue-repair and metabolic cluster. Day 2 (July 24) covers Emideltide/DSIP, Semax, and Epitalon — the sleep, cognition, and longevity cluster, all with roots in Soviet-era Russian bioregulator research.

A positive recommendation doesn’t mean FDA drug approval. It means a licensed 503A pharmacy could legally compound the substance for an individual patient with a prescription — quality-controlled, but still without a proven clinical indication. A negative recommendation doesn’t ban the compound; it just means the grey market remains the only route.

TB-500 (Thymosin Beta-4) — Contested

The pitch: A synthetic fragment of Thymosin Beta-4, a protein naturally present in nearly every human cell. Marketed for systemic injury recovery — muscle strains, tendon damage, wound healing — often stacked with BPC-157.

What’s real: Thymosin Beta-4 itself has been the subject of over 1,000 peer-reviewed publications, and animal safety data is described as excellent. The full-length molecule (under the name RGN-137) has progressed further in legitimate drug development than most peptides on this list, including work on diabetic ulcers and pressure sores.

What’s missing: A 2026 scoping review found the literature genuinely large but noted the persistent gap between biological plausibility, preclinical signal, and direct human clinical evidence for TB-500 specifically (as opposed to full Thymosin Beta-4). Long-term human evidence remains limited. TB-500 has also been on WADA’s Prohibited List since 2011 — a real consideration for any competitive athlete.

Bottom line: Similar shape to BPC-157 — real biology, real animal data, thin human proof for the specific synthetic fragment being sold.

KPV — Speculative to Contested

The pitch: A short tripeptide (Lys-Pro-Val) derived from alpha-MSH, studied for anti-inflammatory effects in gut and skin conditions, including inflammatory bowel disease.

What’s real: The mechanism — melanocortin receptor and NF-κB pathway modulation — is scientifically plausible and has support in preclinical models.

What’s missing: High-quality human data for any specific medical use remains limited. There’s no formal human pharmacokinetic or drug-interaction study. For IBD specifically, KPV does not appear in clinical guidelines as a standard or guideline-supported treatment — it sits outside the evidence base that guides actual patient care for that condition.

Bottom line: Real preclinical mechanism, essentially no human clinical evidence, and no clinical guideline recognizes it as treatment for the conditions it’s marketed against.

MOTS-c — Emerging (Stalled)

The pitch: A 16-amino-acid peptide encoded by mitochondrial DNA rather than nuclear DNA — unusual biology. Naturally upregulated during exercise; proposed to activate AMPK and improve insulin sensitivity, positioning it as a “exercise mimetic” for metabolic health.

What’s real: This is arguably the most legitimately promising compound on the list from a drug-development standpoint. A related compound, CB4211, completed Phase 1a/1b trials for NASH and obesity with promising early safety results.

What’s missing: Development was discontinued — not for safety reasons, but because no pharmaceutical partner advanced it further. As of 2026, there are no active Phase 2 or Phase 3 trials for MOTS-c or any analog registered anywhere. No completed, published human efficacy trials exist. This is a case of genuine scientific promise stalling for business reasons rather than being disproven — which is a different (and in some ways more frustrating) story than the others on this list.

Bottom line: The one peptide here where the evidence gap looks more like abandoned potential than absent proof — but “abandoned potential” still means zero human efficacy data today.

Emideltide (DSIP) — Contested

The pitch: Delta Sleep-Inducing Peptide, a nonapeptide first isolated from rabbit brain in 1977 during slow-wave sleep. Marketed for insomnia and, notably, opioid withdrawal support.

What’s real: The historical research is genuinely old and comes substantially from Russian and Eastern European clinical literature — decades ahead of the English-language peptide conversation. The opioid withdrawal application, if legitimate, would be a significant public health use case.

What’s missing: Mechanism is plausible; human randomized-controlled-trial data is thin by modern standards. Most of the supporting literature predates the trial designs and reporting standards used in current drug development, making direct comparison to a modern therapeutic difficult.

Bottom line: The oldest research base on this list, and the one where “old” doesn’t necessarily mean “well-established” by today’s evidentiary bar.

Semax — Emerging (Outside the US)

The pitch: A synthetic analog of ACTH(4-10), studied for cognitive enhancement, neuroprotection, and stroke recovery. Stimulates BDNF and NGF production and crosses the blood-brain barrier via intranasal administration.

What’s real: Semax is approved in Russia for post-stroke cognitive recovery and traumatic brain injury, with decades of use and a documented safety profile in that context — genuinely one of the most clinically studied neuropeptides globally, just not in US-recognized trial frameworks. The FDA’s review covers cerebral ischemia, migraine, and trigeminal neuralgia.

What’s missing: “Approved in Russia” is doing a lot of work in most marketing copy for this compound, and Russian regulatory approval doesn’t carry the same evidentiary weight as an FDA New Drug Application. US-language clinical data — trials designed and reported to the standards American regulators and clinicians expect — remains limited.

Bottom line: The most internationally credentialed peptide on this list, and a good example of why “approved somewhere” isn’t the same question as “proven here.”

Epitalon — Speculative

The pitch: A tetrapeptide developed by the St. Petersburg Institute of Bioregulation and Gerontology, targeting telomere elongation and marketed as an anti-aging compound. Under FDA review specifically for insomnia — not the broader longevity claims.

What’s real: Telomere elongation is a legitimate area of aging biology, and animal studies have investigated Epitalon’s effects on lifespan and telomerase activity.

What’s missing: The longevity claims rest almost entirely on aging-cohort studies from a single research group — the same structural weakness that undermines BPC-157’s evidence base, and for the same reason: a lack of independent replication makes it hard to know how much of the signal is the compound and how much is the lab. Limited human studies exist, and the FDA’s own review scope for Epitalon is narrower than the anti-aging marketing — insomnia, not longevity.

Bottom line: The biggest gap on this list between the marketing claim (anti-aging) and the regulatory question actually being asked (sleep).

The pattern across all seven

Every peptide on this docket shares a structure: a real, often decades-old, often non-US research tradition; a plausible biological mechanism; and a human evidence base that is either thin, stalled, or geographically disconnected from the US regulatory system. None of that means the underlying biology is fake. It means the gap between “there’s a mechanism” and “this works in a controlled human trial for this population” hasn’t been closed for any of them.

The 2024 PCAC precedent for peptide reviews was lopsided — roughly 11 “Yes” votes against 167 “No” votes across 13 substantive reviews, with even Thymosin Alpha-1 (approved in 35 countries, hundreds of published studies) failing by a wide margin. That history set expectations for broad rejection this time too — which is exactly what made the July 23 result (four straight recommendations, over the FDA staff’s objections) a genuine surprise. See the update at the top of this article.

What a PCAC recommendation actually changes

Worth repeating, because it’s the detail most grey-market marketing glosses over: a positive PCAC vote does not equal an FDA-approved drug. It means a licensed 503A compounding pharmacy could, with a valid physician prescription, legally prepare the compound for an individual patient — under quality and sterility standards that don’t exist in the current grey market. A negative vote doesn’t ban anything; unregulated research-chemical vendors continue operating regardless of the outcome.

The stakes are real either way. The grey-market peptide economy has crossed a $100 million annual run rate, and independent purity testing shows a collapsing quality picture — some peptides have returned failing purity grades on the overwhelming majority of tested samples. A positive PCAC outcome for even one or two of these compounds would give physicians and patients who want quality-controlled access a legal alternative that doesn’t currently exist. A negative outcome across the board pushes that same demand further into a supply chain with no oversight at all.

The Lookout

Peakspan evidence tier: Frontier — Contested to Speculative, varying by peptide

If you take one thing from this article, take this: “under FDA review” is not the same as “on its way to being proven.” Every one of these seven compounds has real biology behind the pitch. None of them has the kind of randomized, controlled, independently replicated human evidence that would let us recommend any of them the way we recommend a protocol in our Field Guides.

We’ll publish individual deep-dive articles on each of these compounds as the evidence and regulatory picture develop — starting with whichever gets the most reader interest or the most consequential FDA follow-up. Both days’ vote outcomes are summarized in the update at the top; any subsequent FDA rulemaking will be added as it’s confirmed.

Updated July 24, 2026 with both days’ PCAC recommendations (six of seven peptides recommended; Emideltide rejected). Any subsequent FDA rulemaking will be added as it’s confirmed. Sourcing: FDA Pharmacy Compounding Advisory Committee meeting materials (July 23–24, 2026, docket FDA-2025-N-6895); STAT News; Reuters; RAPS; FiercePharma. Exact tallies for the day-two votes vary by ±1 across outlets; the direction (Emideltide rejected, Epitalon and Semax recommended) is consistent.